Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Forero

Showing results (101-110 of 179) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent studyJonathan W Friedberg, Philip Cohen, Ling Chen, et al.
Oncotarget|November 27, 2016
Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancerRebecca C Arend, Angelina I Londoño-Joshi, Abhishek Gangrade, et al.
Leukemia & Lymphoma|August 27, 2020
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapyDavid Straus, Graham Collins, Jan Walewski, et al.
Cancer Medicine|January 10, 2014
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancerAndres Forero-Torres, Jeffrey R Infante, David Waterhouse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2012
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphomaAndres Forero-Torres, Sven de Vos, Brad L Pohlman, et al.
Cancer|January 10, 2019
A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinomaSumanta K Pal, Andres Forero-Torres, John A Thompson, et al.
Blood|April 29, 2018
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphomaAnn S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
Oncotarget|May 4, 2018
Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancerRebecca C Arend, Angelina I Londoño-Joshi, Abhishek Gangrade, et al.
British Journal of Haematology|February 13, 2020
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphomaAnn S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
Blood|January 2, 2014
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemiaJohn C Byrd, John M Pagel, Farrukh T Awan, et al.
Pageof 18

Showing results (101-110 of 179) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent studyJonathan W Friedberg, Philip Cohen, Ling Chen, et al.
Oncotarget|November 27, 2016
Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancerRebecca C Arend, Angelina I Londoño-Joshi, Abhishek Gangrade, et al.
Leukemia & Lymphoma|August 27, 2020
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapyDavid Straus, Graham Collins, Jan Walewski, et al.
Cancer Medicine|January 10, 2014
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancerAndres Forero-Torres, Jeffrey R Infante, David Waterhouse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2012
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphomaAndres Forero-Torres, Sven de Vos, Brad L Pohlman, et al.
Cancer|January 10, 2019
A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinomaSumanta K Pal, Andres Forero-Torres, John A Thompson, et al.
Blood|April 29, 2018
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphomaAnn S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
Oncotarget|May 4, 2018
Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancerRebecca C Arend, Angelina I Londoño-Joshi, Abhishek Gangrade, et al.
British Journal of Haematology|February 13, 2020
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphomaAnn S LaCasce, R Gregory Bociek, Ahmed Sawas, et al.
Blood|January 2, 2014
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemiaJohn C Byrd, John M Pagel, Farrukh T Awan, et al.
Pageof 18